My sources tell me that CLDX was having trouble enrolling the trial, because Soliris was being used off-label on these DDD patients. So an update on enrollment would be good.
CLDX will be at ESMO, as far as I know, with more data on 011.
Then CLDX will be at the Society of Neuro-Oncology in November. I expect to hear some news on the Rindo + Avastin trial in glioblastoma.
CLDX will present data some time before the end of the year on CDX-1127 in solid tumors and then data on CDX-1127 in hematological malignancies in 1Q14.
News 
Market Data 
Discover 
